EA201790791A1 - Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов - Google Patents

Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов

Info

Publication number
EA201790791A1
EA201790791A1 EA201790791A EA201790791A EA201790791A1 EA 201790791 A1 EA201790791 A1 EA 201790791A1 EA 201790791 A EA201790791 A EA 201790791A EA 201790791 A EA201790791 A EA 201790791A EA 201790791 A1 EA201790791 A1 EA 201790791A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sulphates
lipids
accumulation
treat
conditions associated
Prior art date
Application number
EA201790791A
Other languages
English (en)
Other versions
EA034524B1 (ru
Inventor
Шуньлинь Жэнь
Цзинь Коунг Ким
Original Assignee
Вирджиния Коммонвелт Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вирджиния Коммонвелт Юниверсити filed Critical Вирджиния Коммонвелт Юниверсити
Publication of EA201790791A1 publication Critical patent/EA201790791A1/ru
Publication of EA034524B1 publication Critical patent/EA034524B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Abstract

Предоставлены способы и композиции для предупреждения и/или лечения симптомов, ассоциированных с расстройствами накопления липидов, вызываемыми пониженной лептиновой активностью и аномальным накоплением липидов. Эти способы включают введение по меньшей мере одного сульфата окисленного холестерина (OCS) индивидууму с указанным расстройством. Расстройство может быть приобретенным или врожденным (наследственным).
EA201790791A 2014-10-10 2015-10-13 Сульфаты окисленного холестерина для лечения пониженной лептиновой активности EA034524B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062260P 2014-10-10 2014-10-10
PCT/US2015/055262 WO2016058000A1 (en) 2014-10-10 2015-10-13 Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorder

Publications (2)

Publication Number Publication Date
EA201790791A1 true EA201790791A1 (ru) 2017-08-31
EA034524B1 EA034524B1 (ru) 2020-02-17

Family

ID=54478210

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790791A EA034524B1 (ru) 2014-10-10 2015-10-13 Сульфаты окисленного холестерина для лечения пониженной лептиновой активности

Country Status (12)

Country Link
US (4) US20170252355A1 (ru)
EP (1) EP3204013A1 (ru)
JP (2) JP2017530174A (ru)
KR (1) KR20170066507A (ru)
CN (1) CN107106576A (ru)
AU (3) AU2015329716A1 (ru)
BR (1) BR112017007025A2 (ru)
CA (1) CA2962500A1 (ru)
EA (1) EA034524B1 (ru)
IL (1) IL251290A0 (ru)
MX (1) MX2017004658A (ru)
WO (1) WO2016058000A1 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
ES2906865T3 (es) 2013-12-24 2022-04-20 Univ Virginia Commonwealth Uso de sulfatos de colesterol oxigenados (OCS) para tratar la insuficiencia hepática aguda
KR102254140B1 (ko) * 2016-04-29 2021-05-24 오르파짐 에이/에스 글루코세레브로시다제 연관 장애를 치료하기 위한 아리모클로몰
CN109983025B (zh) * 2016-08-02 2023-04-04 弗吉尼亚联邦大学 包含5-胆甾烯-3,25-二醇,3-硫酸酯或其盐和至少一种环状寡糖的组合物
CA3031215A1 (en) * 2016-08-02 2018-02-08 Durect Corporation Compositions comprising oxygenated cholesterol sulfate and at least one of polyalkylene glycol, carboxymethyl cellulose and polyoxylglyceride
US20200276211A1 (en) * 2017-11-28 2020-09-03 Viewpoint Therapeutics, Inc. Compounds for treating near vision disorders
WO2021263186A1 (en) * 2020-06-26 2021-12-30 Durect Corporation Use of oxygenated cholesterol sulfates for treating inflammatory conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
WO2006047022A1 (en) * 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
WO2007095462A2 (en) 2006-02-13 2007-08-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US8003795B2 (en) 2007-06-22 2011-08-23 Cvi Pharmaceuticals Limited Compounds and compositions for reducing lipid levels
US9034859B2 (en) * 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
WO2013154752A1 (en) 2012-04-12 2013-10-17 Virgina Commonwealth University A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3β-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS

Also Published As

Publication number Publication date
EP3204013A1 (en) 2017-08-16
JP2017530174A (ja) 2017-10-12
CA2962500A1 (en) 2016-04-14
US20210161913A1 (en) 2021-06-03
US20190083509A1 (en) 2019-03-21
IL251290A0 (en) 2017-05-29
CN107106576A (zh) 2017-08-29
AU2015329716A1 (en) 2017-04-13
JP2021008506A (ja) 2021-01-28
BR112017007025A2 (pt) 2017-12-12
WO2016058000A1 (en) 2016-04-14
KR20170066507A (ko) 2017-06-14
EA034524B1 (ru) 2020-02-17
AU2021202288A1 (en) 2021-05-13
US20200138831A1 (en) 2020-05-07
US20170252355A1 (en) 2017-09-07
MX2017004658A (es) 2017-07-17
AU2021200574A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
EA201790791A1 (ru) Сульфаты окисленного холестерина, используемые для лечения расстройств, вызываемых по меньшей мере одним из состояний, связанных с пониженной лептиновой активностью и накоплением липидов
IL288712B1 (en) Methods for treating abnormal movement disorders
NZ720949A (en) Methods and compositions for treating aging-associated conditions
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2017007852A (es) Formulaciones de acido hipocloroso y metodos para tratar afecciones de la piel.
EP3465212A4 (en) REGULAR FLORAL REGULATION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
WO2016077639A3 (en) Nanovesicular therapies
EP3273973A4 (en) Methods and compositions for treating inflammatory and immunological disorders
MX2022003128A (es) Metodos de tratamiento de trastornos neurodegenerativos en una poblacion de pacientes particular.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
EP3142664A4 (en) Compositions and methods for treating and diagnosing ocular disorders
PH12017500615A1 (en) Ophthalmic composition comprising cyclosporine and trehalose
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
EP3310353A4 (en) COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
EP3506899A4 (en) COMPOSITION AND METHOD FOR DIAGNOSIS AND TREATMENT OF DISEASES OF THE LYMPHATIC SYSTEM
MX2023003924A (es) Metodos de administracion de tratamiento antifibrotico.
MX2017003892A (es) Tratamiento del sindrome de rett.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
MX362391B (es) Métodos de tratamiento de enfermedad renal y otros trastornos.
EP3481432A4 (en) DIAGNOSIS OF DISEASES ASSOCIATED WITH THE COL6 GENE AND RELATED METHODS OF TREATMENT
WO2015113041A3 (en) Compositions and methods for treating autoimmune and inflammatory diseases
PH12016500824A1 (en) Compositions and methods for the treatment of viral diseases with pde4 modulators
EP3398969A4 (en) METHOD FOR DIAGNOSING, TREATING OR PREVENTING MOOD DISORDERS

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM